Bellicum Pharmacueticals Inc. (BLCM) stock starts with “Buy” rating in note to investors by Ladenburg Thalmann

Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) shares closed lower on Wednesday Nov 30 with lighter trade volume than normal after more analysts initiated coverage on the stock.

Meanwhile, the Dow Jones Industrial Average hit an intraday record after opening higher Wednesday, led by the energy sector as hopes rose that the world’s major oil producers are near a deal on limiting output.

The benchmark S&P 500 and Dow were on track to post their largest monthly gains since March.

The S&P 500 SPX, +0.22% gained 5 points, or 0.2%, to 2,209. The Dow Jones Industrial Average DJIA, +0.41% added 62 points, or 0.3%, to 19,184, trading in record territory. The Nasdaq Composite COMP, -0.08% was 7 points, or 0.1%, higher at 5,386.

Analysts at Ladenburg Thalmann initiated coverage on Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) stock, starting the company at Buy. Ladenburg Thalmann currently has a rating of Buy on the shares. As a means of comparison, a number of other analysts have spoken on the company in recent days, and the company has earned a consensus one-year price target of $27.50, above the opening price of $19.73. Bellicum Pharmacueticals Inc. stock has a 52-week high of $23.84. After initiating coverage,, analysts and brokerage firms will subsequently re periodic updates. Price changes targets are not unusual.

Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) shares last traded at $19.05, which represents a dip of $0.11 per share or -0.57% from the previous closing price. Opening at $19.73, they varied from $18.72 and $19.73 throughout the day.

Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) currently has a market cap of 516.35M.

Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) Average Daily Trading Volume

The stock’s average daily volume is 276,205 shares out of a total float 20,977,000 and some 25,845 shares traded hands yesterday, below the average. Look for trading volume to pick up in the coming days as investors often use upticks in trading volume to determine large volume growth or distribution by institutional investors.

As with all possible breakouts, investors watch for volume to be at least 40%-50% higher than normal on the breakout to indicate that fund managers and other professional investors are jumping in.

Institutional sponsorship commonly refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Institutional investors such as these retain teams of analysts researching thousands of stocks, so it is good corroboration to see them taking a postion in a stock you’re considering.

Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By identifying trends, moving averages allow investors to make those trends work in their favor and increase the number of successful trades.

With that in mind, Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) now has a 50-day MA of $18.69 and 200-day MA of $16.37. It has traded in a 52-week range between $7.24 – 23.84 and today’s last price is 20.09%% lower than the 52 week high of $23.84.

Earnings growth is a crucial factor to research when investing in stocks and investors seek companies that have increased their earnings at least 25% or more over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *